blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2398902

EP2398902 - METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  01.09.2023
Database last updated on 04.06.2024
FormerGrant of patent is intended
Status updated on  18.05.2023
FormerExamination is in progress
Status updated on  28.03.2023
FormerGrant of patent is intended
Status updated on  20.11.2022
FormerExamination is in progress
Status updated on  25.10.2022
FormerGrant of patent is intended
Status updated on  22.06.2022
FormerExamination is in progress
Status updated on  20.01.2017
Most recent event   Tooltip06.10.2023Change - divisional application(s)published on 08.11.2023  [2023/45]
Applicant(s)For all designated states
Astellas Pharma Inc.
5-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo 103-8411 / JP
For all designated states
TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
Freiligrathstrasse 12
55131 Mainz / DE
[2020/20]
Former [2020/18]For all designated states
Astellas Pharma Inc.
5-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo 103-8411 / JP
For all designated states
Johannes-Gutenberg-Universität Mainz
Saarstrasse 21
55122 Mainz / DE
Former [2018/42]For all designated states
Ganymed Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
For all designated states
Johannes-Gutenberg-Universität Mainz
Saarstrasse 21
55122 Mainz / DE
Former [2015/23]For all designated states
Ganymed Pharmaceuticals AG
An der Goldgrube 12
55131 Mainz / DE
For all designated states
Johannes-Gutenberg-Universität Mainz
Saarstrasse 21
55122 Mainz / DE
Former [2011/52]For all designated states
Ganymed Pharmaceuticals AG
Freiligrathstrasse 12
55131 Mainz / DE
For all designated states
Johannes- Gutenberg-Universität Mainz
Saarstrasse 21
55122 Mainz / DE
Inventor(s)01 / SAHIN, Ugur
Philipp-Von-Zabern-Platz 1
55116 Mainz / DE
02 / TÜRECI, Özlem
Philipp-Von-Zabern-Platz 1
55116 Mainz / DE
03 / KOSLOWSKI, Michael
Am Ried 23
85764 Oberschleissheim / DE
04 / HELFTENBEIN, Gerd
Nieder-Ohmener Str. 16
35329 Gemünden / DE
05 / KORDEN, Walter
Hüglerstrasse 3
65203 Wiesbaden / DE
06 / WÖLL, Stefan
Pommardstrasse 22a
55299 Nackenheim / DE
07 / OPREA, Gabriela-Elena
Am Ostergraben 4
55128 Mainz / DE
 [2012/51]
Former [2011/52]01 / SAHIN, Ugur
Philipp-Von-Zabern-Platz 1
55116 Mainz / DE
02 / TÜRECI, Özlem
Philipp-Von-Zabern-Platz 1
55116 Mainz / DE
03 / KOSLOWSKI, Michael
Autogenstrasse 50
65933 Frankfurt / DE
04 / HELFTENBEIN, Gerd
Nieder-Ohmener Str. 16
35329 Gemünden / DE
05 / KORDEN, Walter
Hüglerstrasse 3
65203 Wiesbaden / DE
06 / WÖLL, Stefan
Pommardstrasse 22a
55299 Nackenheim / DE
07 / OPREA, Gabriela-Elena
Am Ostergraben 4
55128 Mainz / DE
Representative(s)Schnappauf, Georg, et al
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2023/40]
Former [2011/52]Schnappauf, Georg, et al
Dr. Volker Vossius
Patent- und Rechtsanwaltskanzlei
Geibelstrasse 6
81679 München / DE
Application number, filing date10705304.319.02.2010
[2023/40]
WO2010EP01062
Priority number, dateEP2009000245220.02.2009         Original published format: EP 09002452
EP2009001016406.08.2009         Original published format: EP 09010164
EP2009001413511.11.2009         Original published format: EP 09014135
US20090154167P20.02.2009         Original published format: US 154167 P
US20090231843P06.08.2009         Original published format: US 231843 P
US20090260135P11.11.2009         Original published format: US 260135 P
[2011/52]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010094499
Date:26.08.2010
Language:EN
[2010/34]
Type: A1 Application with search report 
No.:EP2398902
Date:28.12.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 26.08.2010 takes the place of the publication of the European patent application.
[2011/52]
Type: B1 Patent specification 
No.:EP2398902
Date:04.10.2023
Language:EN
[2023/40]
Search report(s)International search report - published on:EP26.08.2010
ClassificationIPC:A61P35/00, A61P35/04, A61P37/04, C12N15/113, A61K31/7088
[2022/18]
CPC:
C12N15/113 (EP,IL,KR,US); G01N33/57449 (EP,KR); A61K31/7088 (EP,CN,IL,KR,US);
A61K39/00 (EP,KR); A61P35/00 (EP); A61P35/04 (EP);
A61P37/04 (EP); C12Q1/6886 (EP,CN); G01N33/57423 (EP,KR);
G01N33/57484 (EP); G01N33/68 (KR); C07K16/28 (EP);
C12Q2600/158 (EP,CN); G01N2800/56 (EP) (-)
Former IPC [2011/52]C12N15/11, A61K31/7088, C07K14/47, C07K16/18, A61K39/00, C12N15/113
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/52]
Extension statesAL16.08.2011
BA16.08.2011
RS16.08.2011
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR DIAGNOSE UND BEHANDLUNG VON KREBS[2011/52]
English:METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER[2011/52]
French:Procédé et compositions pour le diagnostic et le traitement du cancer[2022/49]
Former [2011/52]METHODES ET COMPOSITIONS DE DIAGNOSTIC ET DE TRAITEMENT DU CANCER
Entry into regional phase16.08.2011National basic fee paid 
16.08.2011Designation fee(s) paid 
16.08.2011Examination fee paid 
Examination procedure16.08.2011Amendment by applicant (claims and/or description)
16.08.2011Examination requested  [2011/52]
23.01.2017Despatch of a communication from the examining division (Time limit: M06)
14.07.2017Reply to a communication from the examining division
15.01.2018Despatch of a communication from the examining division (Time limit: M06)
22.08.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
24.10.2018Reply to a communication from the examining division
06.12.2019Despatch of a communication from the examining division (Time limit: M06)
05.06.2020Reply to a communication from the examining division
06.05.2021Despatch of a communication from the examining division (Time limit: M06)
05.11.2021Reply to a communication from the examining division
23.06.2022Communication of intention to grant the patent
25.10.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.11.2022Communication of intention to grant the patent
27.03.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.05.2023Communication of intention to grant the patent
22.08.2023Fee for grant paid
22.08.2023Fee for publishing/printing paid
22.08.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23200924.1
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.01.2017
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
24.10.2018Request for further processing filed
24.10.2018Full payment received (date of receipt of payment)
Request granted
02.11.2018Decision despatched
Fees paidRenewal fee
23.02.2012Renewal fee patent year 03
26.02.2013Renewal fee patent year 04
26.02.2014Renewal fee patent year 05
27.02.2015Renewal fee patent year 06
26.02.2016Renewal fee patent year 07
28.02.2017Renewal fee patent year 08
28.02.2018Renewal fee patent year 09
27.02.2019Renewal fee patent year 10
27.02.2020Renewal fee patent year 11
25.02.2021Renewal fee patent year 12
25.02.2022Renewal fee patent year 13
27.02.2023Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]EP2011886  (GENENTECH INC [US]) [X] 1-23 * page 83, paragraph 353; figures 14,30; claims 1-3,12-15,22,23 ** page 71, paragraphs 283-28 *;
 [X]  - OSANAI MAKOTO ET AL, "Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells.", CANCER SCIENCE OCT 2007, (200710), vol. 98, no. 10, ISSN 1347-9032, pages 1557 - 1562, XP002547907 [X] 1,2,5,9-12,19,22 * abstract * * page 1560; figures 2,3 * * page 1561; figure 5 * * page 1562, column R, paragraph L *

DOI:   http://dx.doi.org/10.1111/J.1349-7006.2007.00569.X
 [X]  - HONG YEON-HEE ET AL, "Up-regulation of the claudin-6 gene in adipogenesis.", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY NOV 2005, (200511), vol. 69, no. 11, ISSN 0916-8451, pages 2117 - 2121, XP002547908 [X] 1,2,22 * abstract * * page 2120; figure 3 *

DOI:   http://dx.doi.org/10.1271/bbb.69.2117
 [X]  - HUANG YU-HUNG ET AL, "Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 3 MAR 2009, (20090210), vol. 106, no. 9, ISSN 1091-6490, pages 3426 - 3430, XP002547909 [X] 1,2,11-15,22,23 * abstract * * page 3430, column L, paragraph LAST * * page 3426, column L, paragraph L *

DOI:   http://dx.doi.org/10.1073/PNAS.0813348106
Examination   - LU K H ET AL, "Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20040515), vol. 10, doi:10.1158/1078-0432.CCR-03-0409, ISSN 1078-0432, pages 3291 - 3300, XP003011115

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-03-0409
    - C. Quan ET AL, "Identification of genes preferentially expressed in mammary epithelial cells of Copenhagen rat using subtractive hybridization and microarrays", Carcinogenesis, GB, (20031001), vol. 24, no. 10, doi:10.1093/carcin/bgg129, ISSN 0143-3334, pages 1593 - 1599, XP055648554

DOI:   http://dx.doi.org/10.1093/carcin/bgg129
by applicantWO9204381
 WO9633265
 WO9633739
 US2002086356
    - BEADLING ET AL., NATURE MEDICINE, (2006), vol. 12, page 1208
    - YUAN ET AL., CYTOTHERAPY, (2006), vol. 8, page 498
    - KRAEFT ET AL., CLIN CANCER RES, (2004), vol. 10, pages 3020 - 8
    - SMIRNOV ET AL., CANCER RES, (2005), vol. 65, pages 4993 - 7
    - ALLARD ET AL., CLIN CANCER RES, (2004), vol. 10, pages 6897 - 904
    - CRISTOFANILLI ET AL., N ENGLJ MED, (2004), vol. 351, pages 781 - 91
    - SMITH; WATERMAN, ADS APP. MATH., (1981), vol. 2, page 482
    - NEDDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
    - PEARSON; LIPMAN, PROC. NATL ACAD. SCI. USA, (1988), vol. 85, page 2444
    - F.M. AUSUBEL ET AL.,, Current Protocols in Molecular Biology, JOHN WILEY & SONS, INC.
    - DR. THOMAS TUSCHL, The siRNA User Guide, LABORATORY OF RNA MOLECULAR BIOLOGY
    - PHILIP SHEPHERD; CHRISTOPHER DEAN, MONOCLONAL ANTIBODIES: A PRACTICAL APPROACH
    - ED HARLOW; DAVID LANE, Antibodies: A Laboratory Manual, ISBN 0879693142
    - EDWARD HARLOW; DAVID LANE; ED HARLOW, Using Antibodies: A Laboratory Manual: Portable Protocol NO, ISBN 0879695447
    - AZORSA ET AL., J. IMMUNOL. METHODS, (1999), vol. 229, pages 35 - 48
    - ANDERSON ET AL., J. IMMUNOL., (1989), vol. 143, pages 1899 - 1904
    - GARDSVOLL, J. IMMUNOL. METHODS, (2000), vol. 234, pages 107 - 116
    - Essential Immunology, BLACKWELL SCIENTIFIC PUBLICATIONS
    - PAUL CALABRESI AND BRUCE A. CHABNER, "Chapter 52 (Antineoplastic Agents", PAUL CALABRESI AND BRUCE A. CHABNER, GOODMAN; GILMAN, The Pharmacological Basis of Therapeutics, 8th Edition,, MCGRAW-HILL, INC
    - ALTMAN ET AL., SCIENCE, (1996), vol. 274, pages 94 - 96
    - DUNBAR ET AL., CURR. BIOL., (1998), vol. 8, pages 413 - 416
    - STANISLAWSKI ET AL., NAT IMMUNOL., (2001), vol. 2, pages 962 - 70
    - KESSELS ET AL., NAT IMMUNOL., (2001), vol. 2, pages 957 - 61
    - OSSENDORP ET AL., IMMUNOL LETT., (2000), vol. 74, pages 75 - 9
    - OSSENDORP ET AL., J EXP. MED., (1998), vol. 187, pages 693 - 702
    - MALOY ET AL., PROC NATL ACAD SCI USA, (2001), vol. 98, pages 3299 - 303
    - SO ET AL., MOL. CELLS, (1997), vol. 7, pages 178 - 186
    - KREIG ET AL., NATURE, (1995), vol. 374, pages 546 - 9
    - SCIENCE, (1995), vol. 268, pages 1432 - 1434
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.